Teratogenic Effects of Pharmaceuticals During Pregnancy: A Comprehensive Review

Abstract

Teratogenicity refers to the ability of certain pharmaceutical agents, chemicals, or environmental factors to interfere with normal embryonic and fetal development resulting in congenital malformations, functional impairments, growth restriction or fetal death. Medication use during pregnancy is common because many women require treatment for acute or chronic medical conditions such as epilepsy, hypertension, diabetes, autoimmune diseases, infections and psychiatric disorders. However, the safety of many medications during pregnancy remains a significant clinical challenge due to physiological changes in the mother, placental drug transfer and the varying susceptibility of the developing fetus at different stages of gestation. Drug exposure during the first trimester, particularly during organogenesis is associated with the highest risk of structural congenital anomalies, whereas exposure during later stages of pregnancy may result in functional abnormalities, impaired fetal growth, or neonatal toxicity. This review provides a comprehensive overview of pharmaceutical teratogenicity, including the biological mechanisms underlying drug-induced congenital anomalies, critical periods of fetal development, placental drug transfer and factors influencing fetal susceptibility. The review discusses major teratogenic medications including antiepileptic drugs, retinoids, antimetabolites, anticoagulants, antihypertensive agents, immunosuppressants and non-steroidal anti-inflammatory drugs with emphasis on their mechanisms of action, teratogenic effects, clinical evidence and recommended risk reduction strategies. Recent advances in pharmacovigilance, pregnancy exposure registries, regulatory frameworks and personalized medicine are also highlighted. In addition, the review emphasizes the importance of preconception counseling, evidence-based prescribing, multidisciplinary collaboration, patient education and continuous fetal monitoring to minimize preventable adverse pregnancy outcomes. Understanding the teratogenic potential of pharmaceuticals is essential for healthcare professionals to balance maternal therapeutic needs with fetal safety. Continuous research improved regulatory guidance and strengthened pharmacovigilance systems are expected to enhance medication safety during pregnancy and contribute to better maternal and neonatal health outcomes.